Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial

Next Previous
Trial Profile

Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cangrelor (Primary) ; Prasugrel (Primary) ; Tirofiban (Primary) ; Aspirin; Aspirin
  • Indications Cardiovascular disorders; Coronary artery disease; Myocardial infarction; Stroke; Thrombosis; Transient ischaemic attacks
  • Focus Pharmacodynamics
  • Acronyms FABOLUS-FASTER

    • Most Recent Events

    • 04 Aug 2020 Primary endpoint has been met. (Inhibition of platelet activity (IPA, %) with LTA-ADP 20 mol/l)
    • 04 Aug 2020 Results published in the Circulation
    • 29 Jun 2020 According to a Medicure media release, results from this study were recently presented virtually at the PCR e-Course Scientific Sessions, due to the cancellation of EuroPCR 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top